Shengfa Su
Impact in
- Otorhinolaryngology top 1%
- Head and Neck Cancer Studies
-
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
Papers in
-
- Lung Cancer Diagnosis and Treatment 19
- Lung Cancer Treatments and Mutations 5
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 2
-
- Effects of Radiation Exposure 7
- Co-authors
- Chong Zhao (2 shared papers)Weiwei Xiao (2 shared papers)Fei Han (2 shared papers)Tai‐Xiang Lu (2 shared papers)Xueming Sun (1 shared paper)Shaomin Huang (1 shared paper)Chengguang Lin (1 shared paper)Xiaowu Deng (1 shared paper)
- Journals
- BMC Cancer (4 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)Frontiers in Oncology (3 papers)Cancer Medicine (3 papers)Anti-Cancer Drugs (2 papers)
- Partner nations
- ChinaNetherlands
In The Last Decade
Shengfa Su
29 papers receiving 649 citations
Shengfa Su's Hit Papers
Peers
Comparison fields: 5 of 43
- Otorhinolaryngology 380
- Pulmonary and Respiratory Medicine 139
- Radiation 27
- Oncology 61
- Radiology, Nuclear Medicine and Imaging 49
Countries citing papers authored by Shengfa Su
This map shows the geographic impact of Shengfa Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengfa Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengfa Su more than expected).
Fields of papers citing papers by Shengfa Su
This network shows the impact of papers produced by Shengfa Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengfa Su. The network helps show where Shengfa Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Shengfa Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities Hit paper breakdown → | 2013 | 461 |
| 2 | 2015 | 38 | |
| 3 | 2022 | 24 | |
| 4 | 2013 | 18 | |
| 5 | 2022 | 18 | |
| 6 | 2014 | 16 | |
| 7 | 2014 | 12 | |
| 8 | 2024 | 8 | |
| 9 | 2014 | 6 | |
| 10 | Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma. | 2019 | 6 |
| 11 | 2020 | 5 | |
| 12 | 2021 | 5 | |
| 13 | 2010 | 4 | |
| 14 | 2021 | 4 | |
| 15 | 2022 | 4 | |
| 16 | 2021 | 3 | |
| 17 | 2022 | 3 | |
| 18 | 2022 | 3 | |
| 19 | 2018 | 2 | |
| 20 | 2023 | 2 |
About Shengfa Su
Shengfa Su is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Oncology, Cardiology and Cardiovascular Medicine and Otorhinolaryngology, having authored 32 papers that have together received 654 indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (19 papers), Effects of Radiation Exposure (7 papers), Lung Cancer Treatments and Mutations (5 papers), Cardiac Fibrosis and Remodeling (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), Chemotherapy-induced cardiotoxicity and mitigation (2 papers) and Head and Neck Cancer Studies (2 papers). The work is most often cited by research in Otorhinolaryngology (380 citations), Pulmonary and Respiratory Medicine (139 citations), Radiation (27 citations), Oncology (61 citations) and Radiology, Nuclear Medicine and Imaging (49 citations). Shengfa Su has collaborated with scholars based in China and Netherlands. Frequent co-authors include Chong Zhao, Weiwei Xiao, Fei Han, Tai‐Xiang Lu, Xueming Sun, Shaomin Huang, Chengguang Lin, Xiaowu Deng, Chunyan Chen and Weiwei Ouyang. Their work appears in journals such as BMC Cancer, International Journal of Radiation Oncology*Biology*Physics, Frontiers in Oncology, Cancer Medicine and Anti-Cancer Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.